Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CCR1 | P32246 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CCR3 | P51677 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1672736 | 1.00 | MEN1 (0.49) | MEN1KMT2ACCR1GAASMN1; SMN2 | |
| SCHEMBL4313992 | 1.00 | MEN1 (0.49) | MEN1KMT2ACCR1GAASMN1; SMN2 | |
| SCHEMBL700122 | 0.99 | MEN1 (0.48) | MEN1KMT2ACCR1GAASMN1; SMN2 | |
| Lithium Ion SCHEMBL700121 | 0.91 | MEN1 (0.47) | MEN1KMT2ACCR1GAASMN1; SMN2 | |
| Lithium Ion SCHEMBL701964 | 0.91 | MEN1 (0.47) | MEN1KMT2ACCR1GAASMN1; SMN2 | |
| SCHEMBL702594 | 0.90 | MEN1 (0.47) | MEN1KMT2ACCR1CCR3 | |
| SCHEMBL702595 | 0.90 | MEN1 (0.47) | MEN1KMT2ACCR1CCR3 | |
| SCHEMBL703073 | 0.90 | MEN1 (0.47) | MEN1KMT2ACCR1CCR3 | |
| SCHEMBL1672707 | 0.84 | MEN1 (0.47) | MEN1KMT2AGAASMN1; SMN2CHRM2 | |
| SCHEMBL4317776 | 0.83 | CHRM2 (0.41) | GAACHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710047-B2 | 5-HT3 receptor modulators, methods of making, and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130310366-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-8501729-B2 | 5-HT3 receptor modulators, methods of making, and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120219641-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| EP-2310019-A2 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | Albany Molecular Research, Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| WO-2009155054-A2 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| US-20090298809-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310366-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | HTR3A, HTR5A, HTR3B | MEN1 2184/4885KMT2A 2954/4885CCR1 1452/4885 |
| US-20090298809-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | HTR3A, HTR5A, HTR3B | MEN1 2184/4885KMT2A 2954/4885CCR1 1452/4885 |
| US-20120219641-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | HTR3A, HTR5A, HTR3B | MEN1 2184/4885KMT2A 2954/4885CCR1 1452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.